Identifying a lead Antibody-drug Conjugate (ADC) with an optimal therapeutic index requires navigating a complex combinatorial matrix. The intricate biological interplay between the naked antibody, linker chemistry, payload mechanism of action, and conjugation site demands empirical evaluation. Traditional, linear conjugation campaigns are prohibitively slow and resource-intensive, often forcing discovery teams to compromise on the number of variants tested.

Pronewbio eliminates this bottleneck. Our high-throughput (HTP) conjugation platform is purpose-built to execute parallel micro-scale conjugations, empowering you to systematically screen hundreds of unique ADC constructs in a fraction of the standard timeline.

Automated Combinatorial Screening Capabilities

Our platform transitions ADC generation from a manual, bespoke process to an automated, data-driven pipeline. We support the rapid assembly and evaluation of diverse molecular libraries, allowing you to fine-tune the Drug-to-Antibody Ratio (DAR) and biophysical stability before committing to scale-up.

• Diverse Conjugation Chemistries: We routinely execute both stochastic and site-directed methodologies in parallel. This includes endogenous cysteine reduction and alkylation, standard lysine amide coupling, and targeted enzymatic approaches (e.g., Sortase A, microbial transglutaminase).
• Precise Stoichiometric Control: Leveraging advanced liquid handling robotics, we precisely modulate reagent equivalents and reaction conditions across 96-well formats to target specific DAR profiles (e.g., strictly DAR 2 or DAR 4) across diverse mAb panels.
• Automated High-Throughput Purification: Unreacted payloads and organic co-solvents are efficiently cleared using automated, micro-scale solid-phase extraction and high-throughput size exclusion chromatography (SEC), ensuring no free drug confounds downstream in vitro cytotoxicity assays.

The Pronewbio HTP Conjugation Workflow

1. Matrix Design: Collaborative selection of mAb candidates, linker architectures (cleavable vs. non-cleavable), and payload classes (e.g., auristatins, maytansinoids, topoisomerase inhibitors) to form the screening grid.
2. Micro-Scale Synthesis: Automated parallel conjugation ranging from 0.1 mg to 5 mg per variant, minimizing the consumption of precious proprietary antibodies and custom payloads.
3. High-Throughput Analytics: Immediate characterization of the micro-batch output.
4. Lead Candidate Selection: Data-rich reporting empowers your team to select the top-performing constructs for intermediate scale-up and in vivo profiling.

Orthogonal Analytical Release

A high-throughput synthesis platform is only as powerful as its analytical backbone. Pronewbio integrates rapid, orthogonal analytical techniques to profile every micro-batch, ensuring that only structurally sound constructs advance to functional screening.

• DAR Distribution Profiling: Automated Hydrophobic Interaction Chromatography (HILIC/HIC) to map the precise DAR distribution and calculate the average DAR.
• Aggregation Analysis: High-throughput SEC-HPLC to identify and quantify high-molecular-weight (HMW) species and ensure monomeric integrity post-conjugation.
• Intact Mass Confirmation: Intact LC-MS analysis to verify the exact mass shift and confirm successful payload attachment.

Accelerate Your ADC Lead Selection

Do not let traditional conjugation bottlenecks dictate the pace of your oncology pipeline. By leveraging our automated, high-throughput platform, your discovery team can confidently evaluate a broader chemical space and identify the most potent, stable ADC construct with an optimized developability profile. Partnering with Pronewbio means transitioning from empirical guesswork to data-driven lead selection, ensuring that only the most viable candidates advance to costly in vivo models.

Ready to Initiate Your Screening Campaign? Connect with our bioconjugation experts today to design your combinatorial matrix and establish a rapid, transparent timeline for your next project.